BNP Paribas Knock-Out MRK 17.05.2.../ DE000PC41EN8 /
16/05/2024 08:07:47 | Chg.0.00 | Bid09:07:11 | Ask09:07:11 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
9.55EUR | 0.00% | 9.80 Bid Size: 3,000 |
10.00 Ask Size: 3,000 |
MERCK KGAA O.N. | - EUR | 17/05/2024 | Call |
GlobeNewswire
00:00
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
15/05
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VIS...
GlobeNewswire
15/05
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...
GlobeNewswire
15/05
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
15/05
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
14/12/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
17/10/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA